TITLE

Botulinum Toxin A Treatment in Unilateral Painful Paravertebral Muscle Spasm: Case Report

AUTHOR(S)
Boylu, Ece; Aşir, Alparslan; Domaç, Füsun Mayda; Saraçoğlu, Mehmet
PUB. DATE
March 2009
SOURCE
Journal of Neurological Sciences;2009, Vol. 26 Issue 1, p92
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Botulinum toxin A (BTX-A) has been used in the treatment of chronic pain since effective pain relief was experienced by sufferers of spasticity and dystonia. In our study we aim to discuss the effectiveness of BTX-A in the treatment of the chronic pain that was refractory to traditional therapeutic options. Our patient had developed disciitis after the operation of lumbar disc herniation (L4-L5) and resultant muscle spasm had been observed 20 days after the operation. He complained of severe back pain with a Visual Analog Scale score of 100 millimeter and Oswestry Low Back Pain Questionnaire score of 50. Intravenous antibiotherapy, analgesics and anti-inflammatory medication, and hyperbaric oxygen treatment were applied, and upon persistence of the complaints BTX-A treatment was planned for univertebral muscle spasm and resultant pain. A total of 140 units of BTX-A (Botox) accompanied by EMG was injected due to the muscle spasm severity, between thoracal 1 and lumbar 5 vertebras where paravertebral muscle spasm was observed. The patient was visited at 1,2,3,4 weeks and at 2, 4, and 6 months. Pain disappeared at the end of the second week while the paravertebral muscle spasm improved at the end of the third week. Patient's complaints did not recur and he was noted to maintain his daily activities. The reduction of pain before the disappearance of the muscle spasm suggests that BTX-A is effective in the treatment of chronic pain refractory to the other therapeutic options.
ACCESSION #
37562760

 

Related Articles

  • Botulinum toxin type B de novo therapy of cervical dystonia. Dressler, Dirk; Bigalke, Hans // Journal of Neurology;Aug2005, Vol. 252 Issue 8, p904 

    Botulinum toxin induced therapy failure type B antibody (BT–B, BT–B–AB) has so far only been reported after previous formation of antibodies against botulinum toxin type A (BT–A, BTA– AB).We wanted to explore the risk of BT-B-AB-induced therapy failure in...

  • Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. Müller, J.; Wenning, G. K.; Wissel, J.; Seppi, K.; Poewe, W. // Journal of Neurology;Mar2002, Vol. 249 Issue 3, p300 

    We investigated the efficacy of botulinum toxin A (BtxA) therapy in patients with atypical parkinsonian disorders (APD) exhibiting different types of disabling focal dystonia unresponsive to oral drug therapy. Eight patients with functionally disabling focal dystonia out of a series of 60...

  • Neuroleptic-Induced Tardive Cervical Dystonia: Clinical Series of 20 Patients. Godeiro-Junior, Clecio; Felício, Andre C.; de Carvalho Aguiar, Patrícia; Borges, Vanderci; Silva, Sonia M. A.; Ferraz, Henrique B. // Canadian Journal of Neurological Sciences;Mar2009, Vol. 36 Issue 2, p222 

    Background: Cervical dystonia (CD) may be classified according to the underlying cause into primary or secondary CD. Previous exposure to neuroleptics is one of the main causes of adult-onset secondary dystonia. There are few reports that characterize the clinical features of primary CD and...

  • Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic Pain. Pickett, Andy // BioDrugs;2010, Vol. 24 Issue 3, p173 

    Clostridial neurotoxins from the botulinum neurotoxin (BoNT) family are protein complexes, derived from the bacterium Clostridium botulinum, which potently inhibit acetylcholine release and result in a reversible blockade of the neuromuscular junction. This feature led to the clinical...

  • Costs and consequences of botulinum toxin type A use. Ruiz, Francis J.; Guest, Julian F.; Lehmann, Almut; Davie, Alison M.; Güttler, Karen; Schlüter, Olaf; Dreiss, Götz // European Journal of Health Economics;Sep2004, Vol. 5 Issue 3, p227 

    This study was a retrospective survey of the management of a cohort of children with cerebral palsy at Seepark Hospital, Germany, who did (cases;n=107) and did not (controls;n=107) receive botulinum toxin injections. Data on healthcare resource use and clinical outcomes over 12 months were...

  • Botulinum Toxin in Medical Therapy. Skorin Jr., Leonid // Review of Optometry;7/15/2004, Vol. 141 Issue 7, p53 

    Focuses on the use of botulinum toxin in medical therapy in the U.S. Treatment of blepharospasm, strabismus, and other ocular muscle disorders; Inhibition of the release of acetylcholine from the nerve terminal; Availability of two immunologically distinct neurotoxins for clinical use in the...

  • Botulinum information.  // British Journal of Community Nursing;Dec2005, Vol. 10 Issue 12, p581 

    The article presents information about a leaflet entitled "Botulinum Toxin: Your Questions Answered," from Ipsen Ltd for people with dystonias. It was initially developed to help the Dystonia Society, the organization dedicated to support of people affected by dystonia, answer questions from...

  • Botulinum toxin for writer's cramp: a randomised, placebo- controlled trial and 1-year follow-up. Kruisdijk, J. J. M.; Koelman, J. H. T. M.; de Visser, B. W. Ongerboer; de Haan, R. J.; Speelman, J. D. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2007, Vol. 78 Issue 3, p264 

    Background: Botulinum toxin type A (BoNT-A) has become the treatment of choice for most types of focal dystonia. Objective: To investigate the efficacy of BoNT-A injections in patients with writer's cramp in a double-blind, randomised, placebo-controlled trial and to evaluate the follow-up...

  • Botulinum Toxin Physiology in Focal Hand and Cranial Dystonia. Karp, Barbara Illowsky // Toxins;Nov2012, Vol. 4 Issue 11, p1404 

    The safety and efficacy of botulinum toxin for the treatment of focal hand and cranial dystonias are well-established. Studies of these adult-onset focal dystonias reveal both shared features, such as the dystonic phenotype of muscle hyperactivity and overflow muscle contraction and divergent...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics